Episode 94

full
Published on:

18th May 2022

Soligenix, Inc. (SNGX) Dr. Chris Schaber Ph.D., CEO

Soligenix, Inc. is a late-stage biopharmaceutical company focused

on developing and commercializing products to treat rare disease where there is

an unmet medical need.

They have two areas of focus: a specialized

biotherapeutics segment dedicated to the development of products for orphan

diseases and areas of unmet medical need such as cutaneous T-cell lymphoma,

oral mucositis, pediatric Crohn’s disease, and psoriasis. Also, a

public health solutions segment to develop vaccines and therapeutics

for military and civilian applications in the areas of ricin exposure, emerging

and antibiotic resistant infectious disease, and viral disease including Ebola,

Marburg and COVID-19.

Next Episode All Episodes Previous Episode

Listen for free

Show artwork for The Wall Street Resource

About the Podcast

The Wall Street Resource
Your resource for microcap discovery and due diligence
As part of the investment process, we have conducted countless CEO and executive interviews, and found this to be an invaluable use of time. We provide The Wall Street Resource, not only to help you leverage your time, but for discovery and a starting point for due diligence.

About your host

Profile picture for Jeffrey Kone

Jeffrey Kone

Managing Member and portfolio manager of a micro-cap fund for over 15 years. Securities experience that encompasses almost all aspects of the industry (buy side, sell side, retail, institutional and investment banking). Degree from University of Southern California with a Bachelor of Science in Business, emphasis in Entrepreneurship.